Overview of Lumasiran Clinical Development Program Presented at the Oxalosis & Hyperoxaluria Foundation (OHF) 14th International Hyperoxaluria Workshop

22 Jun, 2023 Overview of Lumasiran Clinical Development Program Presented at the Oxalosis & Hyperoxaluria Foundation (OHF) 14th International Hyperoxaluria Workshop

We presented an overview of the lumasiran clinical development program, including data from the Phase 3 ILLUMINATE-A, ILLUMINATE-B and ILLUMINATE-C studies, in patients with primary hyperoxaluria type 1 (PH1) at the Oxalosis & Hyperoxaluria Foundation (OHF) 14th International Hyperoxaluria Workshop.

Shasha-Lavsky, et al. “Targeting Glycolate Oxidase for the Treatment of Primary Hyperoxaluria Type 1: Development and Clinical Characterization of Lumasiran, an RNAi Therapeutic.”